We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Globus Medical (GMED) Down 2% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
A month has gone by since the last earnings report for Globus Medical (GMED - Free Report) . Shares have lost about 2% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Globus Medical due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Globus Medical Beats on Q2 Earnings and Revenues
Globus Medical reported second-quarter 2020 adjusted earnings per share (EPS) of 7 cents, which compared favorably with the Zacks Consensus Estimate of a loss of 11 cents. However, the metric declined 13.9% from the year-ago figure.
Adjusted EPS excludes certain non-recurring expenses like amortization of intangibles and acquisition-related costs.
Without the adjustments, the company registered GAAP loss per share of 21 cents per share, reflecting a decline from the year-ago quarter’s EPS of 38 cents.
Revenues
Second-quarter 2020 worldwide sales totaled $148.9 million, down 23.4% (down 23.3% at constant exchange rate or CER) year over year. The reported figure, however, surpassed the Zacks Consensus Estimate by 49.3%.
Quarterly Details
Sales generated in the United States during the quarter under review declined 21.8% year over year due to adverse impacts of the coronavirus pandemic. The pandemic-led impacts on sales were most pronounced in the earlier part of the quarter. However, as the quarter progressed, overall sales improved sequentially from the last reported quarter, led by the U.S. spine business. The company also noted that robotic technology maintained its momentum, which enabled the company to enter into several agreements in June and July.
International sales declined 31.2% from the year-earlier quarter (down 30.5% at CER). The primary reason for the plunge is pandemic-led business disruptions.
Musculoskeletal Solutions products generated revenues of $143.5 million, down 21.4% year over year. Enabling Technologies product revenues of $5.4 million in the quarter reflect a 54.7% plunge from the prior-year figure.
Margin
Gross profit in the reported quarter dropped 34.7% year over year to $98.3 million. Gross margin contracted a huge 1139 basis points (bps) to 65.9% on a 15.1% rise in cost of goods sold to $50.6 million.
Selling, general and administrative expenses in the reported quarter were $80.02 million, down 9.5% from the year-ago quarter. Research and development expenses, however, rose 150.6% to $39.5 million.
Operating loss in the reported quarter was $21.2 million against operating income of $46.4 million year over year.
Cash Position
Globus Medical exited the second quarter with cash and cash equivalents, and short-term marketable securities of $316.7 million compared with $276.9 million at the end of the first quarter.
Notably, the company remains debt free.
Cumulative net cash provided by operating activities at the end of the second quarter was $65.4 million compared with the year-ago $61.8 million.
2020 Guidance
Globus Medical is currently unable to predict the extent or duration of the pandemic’s impact on its financial and operating results. Accordingly, the company has not provided any financial guidance.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in estimates review. The consensus estimate has shifted 38.71% due to these changes.
VGM Scores
At this time, Globus Medical has a poor Growth Score of F, however its Momentum Score is doing a lot better with a C. Following the exact same course, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Globus Medical has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Globus Medical (GMED) Down 2% Since Last Earnings Report: Can It Rebound?
A month has gone by since the last earnings report for Globus Medical (GMED - Free Report) . Shares have lost about 2% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Globus Medical due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Globus Medical Beats on Q2 Earnings and Revenues
Globus Medical reported second-quarter 2020 adjusted earnings per share (EPS) of 7 cents, which compared favorably with the Zacks Consensus Estimate of a loss of 11 cents. However, the metric declined 13.9% from the year-ago figure.
Adjusted EPS excludes certain non-recurring expenses like amortization of intangibles and acquisition-related costs.
Without the adjustments, the company registered GAAP loss per share of 21 cents per share, reflecting a decline from the year-ago quarter’s EPS of 38 cents.
Revenues
Second-quarter 2020 worldwide sales totaled $148.9 million, down 23.4% (down 23.3% at constant exchange rate or CER) year over year. The reported figure, however, surpassed the Zacks Consensus Estimate by 49.3%.
Quarterly Details
Sales generated in the United States during the quarter under review declined 21.8% year over year due to adverse impacts of the coronavirus pandemic. The pandemic-led impacts on sales were most pronounced in the earlier part of the quarter. However, as the quarter progressed, overall sales improved sequentially from the last reported quarter, led by the U.S. spine business. The company also noted that robotic technology maintained its momentum, which enabled the company to enter into several agreements in June and July.
International sales declined 31.2% from the year-earlier quarter (down 30.5% at CER). The primary reason for the plunge is pandemic-led business disruptions.
Musculoskeletal Solutions products generated revenues of $143.5 million, down 21.4% year over year. Enabling Technologies product revenues of $5.4 million in the quarter reflect a 54.7% plunge from the prior-year figure.
Margin
Gross profit in the reported quarter dropped 34.7% year over year to $98.3 million. Gross margin contracted a huge 1139 basis points (bps) to 65.9% on a 15.1% rise in cost of goods sold to $50.6 million.
Selling, general and administrative expenses in the reported quarter were $80.02 million, down 9.5% from the year-ago quarter. Research and development expenses, however, rose 150.6% to $39.5 million.
Operating loss in the reported quarter was $21.2 million against operating income of $46.4 million year over year.
Cash Position
Globus Medical exited the second quarter with cash and cash equivalents, and short-term marketable securities of $316.7 million compared with $276.9 million at the end of the first quarter.
Notably, the company remains debt free.
Cumulative net cash provided by operating activities at the end of the second quarter was $65.4 million compared with the year-ago $61.8 million.
2020 Guidance
Globus Medical is currently unable to predict the extent or duration of the pandemic’s impact on its financial and operating results. Accordingly, the company has not provided any financial guidance.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in estimates review. The consensus estimate has shifted 38.71% due to these changes.
VGM Scores
At this time, Globus Medical has a poor Growth Score of F, however its Momentum Score is doing a lot better with a C. Following the exact same course, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Globus Medical has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.